Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
PPP2R5E Antibody
NCTP01444
Description: Rabbit polyclonal to human PPP2R5E
Application: ELISA, IHC
Reactivity: Human
Catalog #: NCTP01444
$360
1000 Items
Overview
| DESCRIPTION | |
| Species Reactivity | Human. Predicted reacts with mouse, rat. Other species not tested. |
| Isotype | IgG |
| Immunogen | A peptide near the C terminal of human PPP2R5E |
| Accession # | Q16537 |
| Alternative Names | Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform; PP2A B subunit isoform B'-epsilon; PP2A B subunit isoform B56-epsilon; PP2A B subunit isoform PR61-epsilon; PP2A B subunit isoform R5-epsilon |
| Purification | Purified by peptide affinity column. |
| Formulation | Lyophilized with 1% BSA and 0.02% NaN3. |
| Size | 100µg/200µl |
| APPLICATION | |
| ELISA | 1:20,000-1:80,000 |
| Immunohistochemistry | 1:100-1:500 |
| - | For research use only. Optimal dilutions/concentrations should be determined by each laboratory for each application. |
| PREPARATION AND STORAGE | |
| Reconstitution | Reconstitute in 200µl of sterile H2O. |
| Storage | Shipped at ambient temperature. Store immediately at -20°C upon receipt. Avoid repeated freeze-thaw cycles. |
| REFERENCES | |
| - | Wade R, Di Bernardo MC, Richards S, et al. Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. Haematologica 96 (10), 1496-1503 (2011). |